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INTRODUCTION 
Secondary leukemia or therapy-related leukemia (t-AML) is a well recognized 
clinical syndrome that occurs as a late complication after cytotoxic therapy, 
which is believed to be the cause of subsequent mutations. The most 
common one is acute myeloid leukemia, on which this work will be focussed, 
as well as  
the effect of the topoisomerase inhibitor-based therapy, and therapy-
related acute myeloid leukemia mutations. 
MATERIAL AND METHODS 
As a basis for the development of this work, many information 
sources such as paper, reviews, books, on-line official web 
pages and on-line catalogue were consulted. 
 OBJECTIVES 
 The aim of this work is to make a review of the effects of 
chemotherapy on the occurrence of leukemia, focusing on 
topoisomerase inhibitors, and acute myeloid leukemia.  
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As far as survival of patients suffering  from t-AML is concerned, it is 
proven that depending on the kariotype presented the prognose varies. 
With balanced aberrations in chromosomes 5 and 7, the survival is 
higher. 
However, in t-AML cases it is shown that cases presenting a non-favorale 
cytogenetics are more common.  
 
INCIDENCE 
The risk of developing a second malignancy has been 
estimated in the range of 8 % to 12 % at 20 years after 
diagnosis of the first cancer and the incidence increases with 
age. 
It should be emphasized that the proportion of secondary 
acute leukemia is increasing; this is associaated with a 
widespread use of chemotherapy and radiotherapy, which 
increased the survival of patients with cancer and aging . 
The latency time after treatment until the disease is longer 
with alkylating agents , and shorter with  topoisomerase II. 
The average age of the t- AML patients is 69 years.  
 
 
 
PROGNOSIS t- AML 
Myeloid therapy-related leukemia (t-AML) is a clinical syndrome well 
known that appears as a late complication after the cytotoxic therapy6. The 
term “therapy-related” of the leukemia is descriptive and it is based in the 
exposition time of cytotoxic agents of a patient. 
 
SUBTYPES 
Characteristics of the therapy-related leukemia and development 
depends on the exposition to specific agents, the cumulative dose and 
the intensity of the therapy. 
 
Factors influencing the outcome in t - AML 
The t- AML is generally a fatal disease. Some potential factors may 
explain the poor outcome of patients with therapy:  
The persistence of the primary malignancy causes morbidity and 
mortality independent from the failure of the bone marrow caused 
by leukemia  
Damage to the organs and the vascular supply of the previous 
treatment may compromise the ability of these patients to receive 
intensive remission induction chemotherapy or bone marrow 
transplantation .  
The high frequency of unfavorable cytogenetic aberrations arising 
during or after chemoradiotherapy appears to lead to the rapid 
emergence of resistance to chemotherapy in t - AML Stem Cells. 
 
In the classic form of the treatment with alkylating 
agents:  
-Bone marrow resemble the primary tumours of 
MDS.  
 -Partial or total loss of chromosomes 5 and/or 7 
have been reported in more than 90% of the cases. 
-This form of t-MDS /T-LMA is developed usually in 
5-7 years’ time after the chemotherapy and gives a 
bad prognosis. 
Treatment with topoisomerase II inhibitors:   
- Displacements that imply chromosomal bands 
11q23 or 21q22 can imply gene MLL that might 
suffer balanced translocations to the chromosomal 
band 11q23. , or the genes LPM / RARA in the acute 
promyelocitic therapy-related leukemia.  
 
TREATMENT 
CONCLUSIONS: 
During this work I have seen that secondary leukemias are something that 
happens and will happen. So I think it would be good to try to reduce as far 
as possible this risk and to maximize treatment outcomes 
 I also think it would be essential that patients with therapy-related leukemia 
take a test in order to determine cytogenetic mutations that are causing this 
tumor, and receive treatment according to these mutations. 
However animal studies should be made to check the different ways and try 
new therapies against this tumor. 
In conclusion, it is necessary to gain more knowledge of secondary leukemia, 
and identify the optimal therapy administration. 
  
 
 
 
 
 
 
Fig. 1: Prognosis of t- AML9. 
Godley, LA. et Al. 2002 
Fig. 2: Age distribution at diagnosis of 161 patients with 
secondary acute myeloid lekemia. 
Figure 3: Cytologic changes in therapy 
related leukemia  
Figure 4. Genetic pathways identified in 140 
cases of t-MDS and t-AML by Pedersen-
Bjergaard et al.  
Table 1: Survival according to karyotype group for patients with t-AML 
or de novo AML treated by the German AML Cooperative Group 
(AMLCG) 
Figure 5: Desicion tree for the management of t-AML  
